This goes into a similar direction as the study by Lee et al. who examined TERT promotor mutation status in combination with BRAF V600E mutations in a cohort of 504 consecutive patients with sub-centimetric papillary thyroid carcinomas measuring. The gene discussed is BRAF; the disease is thyroid gland papillary carcinoma.